tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Immutep’s Eftilagimod Alfa Trials to be Showcased at ESMO 2025

Story Highlights
Immutep’s Eftilagimod Alfa Trials to be Showcased at ESMO 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Immutep Ltd ( (AU:IMM) ) has shared an announcement.

Immutep Limited announced that three abstracts related to its clinical trials for the MHC Class II agonist, eftilagimod alfa, have been accepted for presentation at the European Society for Medical Oncology Congress 2025. This includes a Phase II trial in soft tissue sarcoma, a Phase I trial in non-small cell lung cancer (NSCLC), and a pivotal Phase III trial in NSCLC. These presentations at a prestigious oncology congress underscore the potential impact of Immutep’s therapies on cancer treatment, highlighting its strategic positioning in the immunotherapy field.

The most recent analyst rating on (AU:IMM) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.

More about Immutep Ltd

Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a leader in exploring and advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), utilizing its potential to modulate the immune response. Immutep aims to deliver innovative treatment options to patients and maximize shareholder value.

YTD Price Performance: -28.77%

Average Trading Volume: 3,443,682

Technical Sentiment Signal: Sell

Current Market Cap: A$381.6M

For a thorough assessment of IMM stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1